FDA removes 12 peptides from the Category 2 list
On April 15, 2026, the FDA published a Federal Register notice (docket FDA-2025-N-6895) removing twelve peptide bulk drug substances — including BPC-157, TB-500, Epitalon, and Semax — from Category 2 (substances presenting significant safety risks). A Pharmacy Compounding Advisory Committee meeting is scheduled for July 23–24, 2026 to review the first seven peptides for potential Category 1 status.
Category 2 removal is interim: these peptides are no longer flagged as significant safety risks, but legal 503A compounding still requires addition to the Category 1 list or a USP monograph. Timeline for full Category 1 status: late 2026 – early 2027 (expected).
What actually changed on April 15
The FDA maintains three operational buckets for bulk drug substances used in 503A compounding:
- Category 1: substances evaluated and approved for 503A compounding. Pharmacies may source and compound these with a valid prescription.
- Category 2: substances the FDA has flagged as posing significant safety risks. Compounding is effectively prohibited.
- Under review: substances pending Pharmacy Compounding Advisory Committee (PCAC) consideration — neither approved nor restricted in the meantime.
The April 15 action moved twelve peptides out of Category 2 and into the pending-review bucket. They are no longer classified as significant safety risks, but they have not yet been added to Category 1. Full legal compounding access returns only after PCAC review and a subsequent Category 1 determination.
For patients, this is meaningful progress — it signals the FDA's willingness to revisit compounded peptide access through a transparent, scientifically-reviewed process. For compounding pharmacies, it means formal clarity is coming in months, not years.
Reclassification timeline
Secretary Robert F. Kennedy Jr. signaled that the FDA would revisit its 2023 Category 2 listings for approximately 14 peptides — setting the agenda for regulatory review.
Federal Register notice (docket FDA-2025-N-6895) announced the removal of twelve peptide bulk drug substances from the Category 2 list. Effective seven calendar days from publication. Removal is interim — substances are no longer flagged as presenting significant safety risks, but have not yet been added to the Category 1 approved list.
FDA docket FDA-2025-N-6895 open for public comments on the seven peptides scheduled for the July PCAC meeting.
Two-day public meeting reviewing seven peptides — BPC-157, TB-500, KPV, MOTS-c, Emideltide (DSIP), Epitalon, and Semax — for potential Category 1 status and legal 503A compounding.
After PCAC recommendations and further FDA review, final determinations on the seven peptides. Category 1 status would permit compounding by 503A pharmacies with a valid prescription.
Five additional peptides — GHK-Cu (all routes), LL-37, PEG-MGF, Dihexa Acetate, and Melanotan II — scheduled for later advisory committee review.
July 2026 PCAC review — 7 peptides
These seven peptides are scheduled for the July 23–24, 2026 advisory committee meeting. Category 1 determination expected late 2026 – early 2027.
BPC-157
Body Protection Compound
Tissue repair & gut health
Most widely recognized peptide in regenerative medicine. PCAC review for ulcerative colitis and wound-healing use cases.
TB-500
Thymosin Beta-4 fragment
Tissue repair & recovery
Wound healing, tissue repair, injury recovery. Paired frequently with BPC-157 in clinical protocols.
KPV
Lysine-Proline-Valine tripeptide
Anti-inflammatory / gut health
C-terminal tripeptide of α-MSH. PCAC review for inflammatory bowel disease applications.
MOTS-c
Metabolic / exercise mimetic
Mitochondrial-derived peptide studied for metabolic health and obesity applications.
Emideltide (DSIP)
Delta Sleep-Inducing Peptide
Sleep & recovery
Naturally occurring neuropeptide. PCAC review for opioid withdrawal and sleep applications.
Epitalon
Epithalon
Anti-aging / telomerase
Tetrapeptide studied for telomerase activation and longevity. Moved to PCAC review July 24.
Semax
Nootropic / neuroprotective
Synthetic ACTH analog. PCAC review covers cognitive and neuroprotective applications.
Later review — 5 additional peptides
Also removed from Category 2 on April 15, but scheduled for a later PCAC review by February 2027.
GHK-Cu
Copper peptide (all routes)
Skin & tissue regeneration
Copper-binding peptide. Removed from Category 2 but scheduled for later PCAC review (by Feb 2027).
LL-37
Cathelicidin
Antimicrobial / immune
Host-defense peptide with antimicrobial and wound-healing activity.
PEG-MGF
Pegylated Mechano Growth Factor
Muscle repair
Pegylated splice variant of IGF-1. Longer review timeline.
Dihexa Acetate
Nootropic / neuroprotective
Angiotensin IV analog studied for cognitive enhancement.
Melanotan II
Pigmentation / sexual health
Melanocortin agonist. Removed from Category 2 pending further review by Feb 2027.
What this does not mean
Even after Category 1 status, these peptides are not FDA-approved medications. They are ingredients permitted in custom-compounded prescriptions.
A licensed provider's prescription is still required. No reclassification will change this — 503A compounding is a prescription pathway, not an over-the-counter one.
Removal from Category 2 ≠ addition to Category 1. Pharmacies still cannot legally compound these substances until the PCAC review concludes and the FDA issues a Category 1 determination.
Research-use-only vendors remain a separate regulatory issue. Reclassification specifically affects the 503A compounding pathway — not research chemical distribution.
What's legally compoundable right now
These peptides and compounds are currently Category 1, have a USP monograph, or are components of FDA-approved drugs — meaning licensed 503A pharmacies can legally compound them today with a valid prescription.
Previously FDA-approved (Geref) — growth hormone secretagogue
FDA-approved drug
FDA-approved drug for HSDD
Category 1 on 503B list — hormonal/reproductive
Category 1 — also available OTC as supplement
Category 1 tripeptide antioxidant
Vasoactive intestinal peptide — Category 1
FDA-approved drug with USP monograph
FDA-approved drug
GLP-1 therapy is available now
While the peptide review timeline plays out, prescription GLP-1 medications like Zepbound are available today through Valitide. Check your eligibility in minutes.
Check Your EligibilityInformation current as of April 19, 2026. FDA rulemaking is an evolving process — check FDA.gov or the Federal Register docket FDA-2025-N-6895 for the latest status.